The PI3K/Akt Pathway in Tumors of endocrine Tissues

被引:99
|
作者
Robbins, Helen Louise [1 ]
Hague, Angela [2 ]
机构
[1] Univ Hosp Coventry & Warwickshire, Dept Gen Surg, Coventry, W Midlands, England
[2] Univ Bristol, Sch Cellular & Mol Med, Sch Oral & Dent Sci, Bristol, Avon, England
来源
FRONTIERS IN ENDOCRINOLOGY | 2016年 / 6卷
关键词
thyroid tumors; parathyroid tumors; pituitary tumors; adrenocortical carcinoma; phaeochromocytoma; neuroblastoma; gastroenteropancreatic neuroendocrine tumors; Akt/PKB kinases; GROWTH-FACTOR RECEPTOR; THYROID-CANCER CELLS; MORPHOPROTEOMICS DEMONSTRATES ACTIVATION; AKT ACTIVATION; PHOSPHATIDYLINOSITOL; 3-KINASE/AKT; MAMMALIAN TARGET; MTOR PATHWAY; ADRENOCORTICAL CARCINOMA; NEUROENDOCRINE TUMORS; PITUITARY-ADENOMAS;
D O I
10.3389/fendo.2015.00188
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a key driver in carcinogenesis. Defects in this pathway in human cancer syndromes such as Cowden's disease and Multiple Endocrine Neoplasia result in tumors of endocrine tissues, highlighting its importance in these cancer types. This review explores the growing evidence from multiple animal and in vitro models and from analysis of human tumors for the involvement of this pathway in the following: thyroid carcinoma subtypes, parathyroid carcinoma, pituitary tumors, adrenocortical carcinoma, phaeochromocytoma, neuroblastoma, and gastroenteropancreatic neuroendocrine tumors. While data are not always consistent, immunohistochemistry performed on human tumor tissue has been used alongside other techniques to demonstrate Akt overactivation. We review active Akt as a potential prognostic marker and the PI3K pathway as a therapeutic target in endocrine neoplasia.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] Frequent Aberrant Activation of the PI3K/Akt/mTOR Pathway in Pancreatic Endocrine Tumors
    Zhou, X. P.
    Frankel, W. L.
    Bloomston, M.
    Iwenofu, O. H.
    Bellizzi, A. M.
    LABORATORY INVESTIGATION, 2009, 89 : 327A - 327A
  • [2] Frequent Aberrant Activation of the PI3K/Akt/mTOR Pathway in Pancreatic Endocrine Tumors
    Zhou, X. P.
    Frankel, W. L.
    Bloomston, M.
    Iwenofu, O. H.
    Bellizzi, A. M.
    MODERN PATHOLOGY, 2009, 22 : 327A - 327A
  • [3] Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
    LoRusso, Patricia Mucci
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3803 - +
  • [4] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [5] PI3K/Akt Pathway Mutations in Retinoblastoma
    Cohen, Yoram
    Merhavi-Shoham, Efrat
    Avraham-Lubin, Bat Chen R.
    Savetsky, Michael
    Frenkel, Shahar
    Pe'er, Jacob
    Goldenberg-Cohen, Nitza
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2009, 50 (11) : 5054 - 5056
  • [6] PI3K/AKT/mTOR pathway in angiogenesis
    Karar, Jayashree
    Maity, Amit
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2011, 4
  • [7] Activation of the PI3K/Akt pathway in neuroblastoma
    Sartelet, Herve
    Castaing, Marine
    Fabre, Monique
    Bosq, Jacques
    Rougemont, Anne-Laure
    Michieis, Stefan
    Vassal, Gilles
    VIRCHOWS ARCHIV, 2007, 451 (02) : 130 - 130
  • [8] The PI3K/Akt/mTOR signaling pathway
    Dennis, P. A.
    ANNALS OF ONCOLOGY, 2011, 22 : 19 - 19
  • [9] Overview of the PI3K/Akt/mTOR pathway
    Dennis, P. A.
    ANNALS OF ONCOLOGY, 2008, 19 : 21 - 21
  • [10] Activation of the PI3K/Akt pathway in neuroblastoma
    Sartelet, H.
    Castain, M.
    Fabre, M.
    Bosq, J.
    Rougemont, A.
    Michiels, S.
    Vassal, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)